PYTEST- urea, c-14 capsule
Avent, Inc.

---------

PYtest\(^1\) (\(^{14}\text{C}-\text{Urea Capsules})

**Description**

PYtest\(^1\) (\(^{14}\text{C}-\text{urea capsules}) is intended for use in the detection of gastric urease as an aid in the diagnosis of *Helicobacter pylori (H. pylori)* infection in the human stomach. The test utilizes a liquid scintillation counter for the measurement of \(^{14}\text{CO}_2\) in breath samples. The capsules are to be used when analysis is planned at the site where the sample is taken.

PYtest\(^1\) capsule is a gelatin capsule for oral administration containing 1 µCi of \(^{14}\text{C}\) labeled urea. The urea is adsorbed on sugar spheres and colored yellow with fluorescein.

---

\(^1\) Registered Trademark or Trademark of Kimberly-Clark Worldwide, Inc.

**Data on \(^{14}\text{C}\)-urea**

Structural Formula (\(^{14}\text{C}\)-urea): \(\text{NH}_2^{14}\text{CONH}_2\)

Radiation emission: beta-emission, 49 keV\(_{\text{mean}}\), 156 keV\(_{\text{max}}\), no other emissions

External emission: No external radiation hazard. Low-energy beta emissions only.

Maximum range of 0.3 mm in water.

Radiological Half-life: 5730 years

Maximum effective dose equivalent (EDE): 0.3 mrem/µCi

**Clinical Pharmacology**

The urease enzyme is not present in mammalian cells, so the presence of urease in the stomach is evidence that bacteria are present. The presence of urease is not specific for *H. pylori*, but other bacteria are not usually found in the stomach. The principle of the breath test is shown in Figure 1.

**Figure 1: Principle of Breath Test**
To detect \textit{H. pylori}, urea labeled with $^{14}$C is swallowed by the patient. If gastric urease from \textit{H. pylori} is present, urea is split to form \textit{CO$_2$} and \textit{NH}_3 at the interface between the gastric epithelium and lumen and \textit{CO$_2$} is absorbed into the blood and exhaled in the breath.

Following ingestion of the capsule by a patient with \textit{H. pylori}, \textit{CO$_2$} excretion in the breath peaks between 10 and 15 minutes and declines thereafter with a biological half-life of about 15 minutes. \textit{C}-urea that is not hydrolyzed by \textit{H. pylori} is excreted in the urine with a half-life of approximately 12 hours. About 10% of the \textit{C} remains in the body at 72 hours and is gradually excreted with a biological half-life of 40 days.

**Clinical Studies**

Two studies were performed. In both studies, patients with gastrointestinal symptoms underwent the breath test and an endoscopy. During the endoscopy, biopsy samples were taken from the antral gastric mucosa for histological analysis (2 samples, Giemsa stain) and rapid urease test (1 sample, CLOtest$^1$). Breath samples were mailed to the TRI-MED lab where they were read in a liquid scintillation counter. Results were reported as disintegrations per minute (DPM). Analysis for accuracy used the ten minute breath sample. A breath sample DPM $<50$ was defined as a negative result. DPM $\geq 200$ was defined as a positive result. DPM in the range of 50–199 was classified as indeterminate.

**STUDY 1**

Of 186 patients who had histopathology and CLOtest$^1$ (80 men, 106 women), 53 were infected with \textit{H. pylori} as determined by agreement between histology and CLOtest$^1$. The study results are summarized below:
Table 1: Study #1 (n = 186, Indeterminate results included)

<table>
<thead>
<tr>
<th>H. pylori</th>
<th>Histology and CLOtest&lt;sup&gt;1&lt;/sup&gt;</th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Positive</td>
<td>51</td>
<td>8</td>
<td>59</td>
</tr>
<tr>
<td>PYtest&lt;sup&gt;1&lt;/sup&gt; (DPM 10 min.)</td>
<td>Indeterminate</td>
<td>1</td>
<td>8</td>
<td>9</td>
</tr>
<tr>
<td>Total</td>
<td>Negative</td>
<td>1</td>
<td>117</td>
<td>118</td>
</tr>
<tr>
<td></td>
<td>Total</td>
<td>53</td>
<td>133</td>
<td>186</td>
</tr>
</tbody>
</table>

Notes: PYtest<sup>1</sup> at 10 min. was compared to the gold standard of biopsy results in which histology and CLOtest<sup>1</sup> concurred. Patients who did not have both biopsy tests performed, or in whom the tests differed, were excluded from analysis. There was no statistical difference in test accuracy based on gender of patient.

ppv = positive predictive value (true positive divided by total PYtest<sup>1</sup> positive)

npv = negative predictive value (true negative divided by total PYtest<sup>1</sup> negative)

 STUDY 2

Breath tests were performed on 436 outpatients attending gastroenterology practices at sites in the United States. Seventy-six patients (40 men, 36 women) who had histology and CLOtest<sup>1</sup> were evaluated. The results are summarized below:

Table 2: Study #2 (n = 76, Indeterminate results included)

<table>
<thead>
<tr>
<th>H. pylori</th>
<th>Histology and CLOtest&lt;sup&gt;1&lt;/sup&gt;</th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Positive</td>
<td>22</td>
<td>0</td>
<td>22</td>
</tr>
<tr>
<td>PYtest&lt;sup&gt;1&lt;/sup&gt; (DPM 10 min.)</td>
<td>Indeterminate</td>
<td>4</td>
<td>2</td>
<td>6</td>
</tr>
<tr>
<td>Total</td>
<td>Negative</td>
<td>1</td>
<td>47</td>
<td>48</td>
</tr>
<tr>
<td></td>
<td>Total</td>
<td>27</td>
<td>49</td>
<td>76</td>
</tr>
</tbody>
</table>

Notes: PYtest at 10 min. was compared to the gold standard of biopsy results in which histology and CLOtest concurred. Patients who did not have both biopsy tests performed, or in whom the tests differed, were excluded from analysis. There was no statistical difference in test accuracy based on gender of patient.

ppv = positive predictive value (true positive divided by total PYtest<sup>1</sup> positive)

npv = negative predictive value (true negative divided by total PYtest<sup>1</sup> negative)

Indications and Usage

PYtest<sup>1</sup> (14C-Urea breath test) is indicated for use in the detection of gastric urease as an aid in the diagnosis of H. pylori infection in the human stomach. The test utilizes a liquid scintillation counter for the measurement of 14CO2 in breath samples.

Contraindications

None
Warnings
None

Precautions

General
After the patient ingests the $^{14}$C-urea capsule, the sample collected for test purposes is for in vitro diagnostic use only.

A false positive test could occur in patients who have achlorhydria. Very rarely, a false positive test may occur due to urease associated with Helicobacters other than \textit{H. pylori} (i.e. \textit{Helicobacter heilmanni}).

Limitations of the Test
- The test has been evaluated in outpatients before elective endoscopy.
- Test results should be evaluated with clinical signs and patient history when diagnosing \textit{H. pylori} infection.
- The performance characteristics of the test have not been established for monitoring the efficacy of antimicrobial therapies for the treatment of \textit{H. pylori} infection.
- A negative result does not completely rule out the possibility of \textit{H. pylori} infection. If clinical signs and patient history suggest \textit{H. pylori} infection, repeat the PYtest$^1$ or use an alternative diagnostic method.

Radioactivity
Persons concerned about very low doses of radioactivity may postpone the test or may decide to use an alternative means of diagnosis. The test produces radiation exposure equal to 24 hours of normal background. In animal experiments, such low doses of radiation do not carry measurable risk.

Preclinical studies were not conducted on $^{14}$C-urea. The estimated dose equivalent received from a single administration of PYtest$^1$ ($1 \mu$Ci $^{14}$C) is about 0.3 mrem.

Information for Patients
It is necessary for the patient to fast for 6 hours before the test. The patient should also be off antibiotics and bismuth for 1 month, and proton pump inhibitors and sucralfate for 2 weeks prior to the test. Instruct the patient not to handle the capsule directly as this may interfere with the test result. The capsule should be swallowed intact. Do not chew the capsule.

Carcinogenesis, mutagenesis, impairment of fertility
No studies have been conducted with $^{14}$C-urea to evaluate its potential for carcinogenicity, impairment of fertility, or mutagenicity.

Drug Interactions
Antibiotics, proton pump inhibitors, sucralfate, and bismuth preparations are known to suppress \textit{H. pylori}. Ingestion of antibiotics or bismuth within 4 weeks and proton pump inhibitors or sucralfate within 2 weeks prior to performing the test may give false negative results.

Pregnancy
Pregnancy category C
Animal reproduction studies have not been conducted with PYtest$^1$ ($^{14}$C-urea). It is also not known whether PYtest$^1$ can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. PYtest$^1$ should be given to a pregnant woman only if clearly needed.
Nursing Mothers

It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when PYtest is administered to a nursing woman.

Pediatric Use

Clinical studies in children have not been conducted. However, PYtest is expected to work the same in children as in adults. While the dose (1 capsule) does not need to be adjusted, the child must be able to swallow the intact capsule and blow into a straw.

Adverse Reactions

No adverse reactions were reported in clinical trials.

Overdosage

Risk from radiation is negligible even with a 1000 capsule overdose (0.3 rem). If overdose occurs, the patient may drink one glass of water (150 ml) every hour to hasten excretion of the isotope. Maximum excretion of urea is achieved at a urine output of ≥ 2.0 ml/min.

Dosage and Administration

Materials Needed but not Provided

FOR ANALYSIS AT TEST SITE
BREATH SAMPLE COLLECTED INTO BALLOON
(RECOMMENDED METHOD; SEE FIGURE 2)

- Breath test report form
- Stopwatch/Timer capable of timing an interval up to 10 minutes
- Marking pen
- 1 – 20 ml scintillation vial
- Breath transfer pump
- Pipette (10 ml) for measuring fluids
- Collection fluid (2.5 ml/vial)
- Scintillation fluid (10 ml/vial)
- 1 – Mylar collection balloon
- 1 – Straw
- 2 – Needles
- 2 – 30 ml medicine cups
- Water (40 ml)
- Any gas pump that is airtight and has a flow rate between .5 and 1 liter per minute may be used.

Figure 2: Other Components
FOR ANALYSIS ON SITE.
BREATH SAMPLE COLLECTED INTO VIAL

CAUTION: Kimberly-Clark does not endorse breath sample collection by this method because patients might come into direct contact with the hyamine.

- Breath test report form
- Stopwatch/Timer capable of timing an interval up to 10 minutes
- Safety trap (Figure 3)
- 1 – Straw
- 1 – 20 ml scintillation vial
- Marking pen
- Pipette (10 ml) for measuring fluids
- Collection fluid (2.5 ml/vial)
- Scintillation fluid (10 ml/vial)

**Figure 3: Typical Safety Trap**

Dosage
One Pytest capsule.

**Procedural Notes**
- Inform the patient to fast for 6 hours prior to the test.
- The patient should be off antibiotics and bismuth for 1 month, and proton pump inhibitors and sucralfate for 2 weeks prior to the test.
- Have patient sitting at rest while doing the test.
- The capsule should not be handled directly as this may interfere with the test result.
- To avoid contamination by bacteria in the mouth, the capsule should be swallowed intact. Do not chew capsule.

**Step by Step Procedure for Balloon**

### Breath Sample Collection by Balloon

| Before the test | 1. Label balloon and fill in breath test report form.  
2. Check that all materials are present. |
| Minus 1 minute | 1. Open the package containing the $^{14}$C-urea capsule and 1 minute tip the capsule into the empty 30 ml cup. Do not handle the capsule directly.  
2. Hand the cup to the patient.  
3. Fill the second cup with 20 ml lukewarm water. |
| 0 minute | 1. Ask the patient to tip the capsule directly into his/her mouth, then swallow it with the 20 ml of lukewarm water.  
2. Start the stopwatch when the patient swallows the capsule.  
3. Discard waste (e.g., capsule packaging, used straws) according to your facility's regulations. |
| 3 minutes | Ask the patient to drink another 20 ml of lukewarm water (in case the capsule may have lodged in the esophagus and not yet reached the gastric mucosa). |
| 10 minutes | 1. Push a drinking straw into the neck of the balloon.  
2. Ask the patient to hold his/her breath for 5–10 seconds, then blow up a balloon with a slow breath through the straw, filling the balloon completely.  
3. Tie the neck of the balloon into a tight knot.  
4. Check that the balloon label and the breath test report form are completed correctly. |
| After sample collection | See test analysis procedure. |

### Breath Sample Collection by Vial

| Before the test | 1. Label vial and fill in breath test report form. Vial label should include the patient's name, date of sample collection and time sample is taken.  
2. Check that the vial contains 2.5 ml of collection fluid (1.5 ml methanol, 1.0 ml 1 molar hyamine, two drops thymolphthalein |

CAUTION: Kimberly-Clark does not endorse the collection of breath samples by this method for patient safety reasons.

<table>
<thead>
<tr>
<th>Time</th>
<th>Activity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Minus 2 minutes</td>
<td>Attach a straw to the safety trap (Figure 3).</td>
</tr>
</tbody>
</table>
| Minus 1 minute | 1. Open the package containing the 14C-urea capsule and tip the capsule into the 30 ml cup. Do not handle the capsule directly.  
2. Hand the cup to the patient.  
3. Fill the second cup with 20 ml lukewarm water. |
| 0 minute   | 1. Ask the patient to tip the capsule directly into his/her mouth, then swallow it with the 20 ml of lukewarm water.  
2. Start the stopwatch when the patient swallows the capsule.  
3. Discard waste (e.g., capsule packaging, used straw) according to your facility's regulations. |
| 3 minutes  | Ask the patient to drink another 20 ml of lukewarm water (in case the capsule may have lodged in the esophagus and not yet reached the gastric mucosa). |
| 10 minutes | Ask the patient to hold his/her breath for 5–10 seconds, then blow bubbles into the collection fluid via the safety trap. The patient should blow bubbles until the fluid turns clear. Put lid on vial. |
| After sample collection | See test analysis procedure.                                                                                                           |

**Test Analysis Procedure**

**General Information**
- The collection fluid contains hyamine, methanol and a pH indicator. Hyamine is a corrosive caustic alkali. If you are using the vial method and collecting breath directly into the collection fluid you must supervise the patient and ensure that a safety trap is used.
- The amount of hyamine (1 ml of 1/m) and methanol (2.5 ml) in one collection vial is not sufficient to cause serious poisoning. Local irritation to skin or mucous membranes is likely when the solution is blue. After collecting CO$_2$ the collection fluid turns clear. At this point it is less dangerous because the pH is near neutral.
- If the collection fluid splashes onto the skin or eyes, wash immediately with water. If the collection fluid is accidentally ingested, wash the mouth with water and have the patient drink 250 ml of water immediately. Consult your poison information center for further facts on hyamine.
- Scintillation fluid comes in many formulations. It is usually a mixture of toluene and various cyclic hydrocarbons. It is flammable. Biodegradable formulations do exist. Consult your supplier if you have questions.

**BALLOON READ ON-SITE:**
1. Add 2.5 ml collection fluid to each vial.  
2. Label the scintillation vial lid to match the label on the balloon.  
3. Attach a needle to the inlet and outlet tubes on the pump.  
4. Turn on pump. Allow to run for about 15 seconds.  
5. Put needle from the rigid outlet tube in a vial until it makes bubbles in the collection fluid.
6. Pierce the label of a filled balloon with the other needle and hold it in a stable position. (Do not pierce the balloon anywhere else or it may tear. Do not squeeze the balloon.)

7. After 2–3 minutes the collection fluid should turn colorless.

8. After the collection fluid is colorless, remove the needles from the balloon and collection fluid and discard according to your facility protocol.

9. Change needles between patients.

10. Turn off pump after last patient sample is transferred.

11. Double check that the label on the vial lid matches the label on the balloon.

12. Add 10 ml scintillation fluid to each vial and mix fluid.

13. Count the sample in liquid scintillation counter for 5 minutes or as directed by the liquid scintillation counter manufacturer. (Note that values of 50–300 DPM can occur immediately after the addition of the scintillation fluid due to chemiluminescence. Chemiluminescence decays rapidly over an hour or two and will reveal itself by falling counts. Read the sample repeatedly until values 10 minutes apart are similar. If DPM is still 50–300, you should allow the sample to settle for 12–24 hours before re-testing.)

14. Include a standard and a blank control vial in each run.

**VIALS READ ON-SITE**

See steps 12–14 under "Balloon read on-site."

**Quality Control**

A minimum of 1 mmol of CO₂ is required to perform analysis of a breath sample. The amount of breath required to provide 1 mmol of CO₂ varies depending on the amount of CO₂ the patient is producing. Since a full balloon typically contains at least 1 mmol of CO₂, the balloon should be completely filled.

**Results**

<table>
<thead>
<tr>
<th>Interpretation of results (10 minute sample)</th>
<th>Result</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt; 50 DPM</td>
<td>Negative for <em>H. pylori</em></td>
<td></td>
</tr>
<tr>
<td>50–199 DPM</td>
<td>Indeterminate for <em>H. pylori</em></td>
<td></td>
</tr>
<tr>
<td>≥ 200 DPM</td>
<td>Positive for <em>H. pylori</em></td>
<td></td>
</tr>
</tbody>
</table>

The indeterminate result should be evaluated by repeating the PYtest¹ or using an alternative diagnostic method. If repeat breath testing is undertaken, careful history to exclude confounding factors should be obtained. If confounding factors are identified, wait an appropriate time (refer to table 3) before repeating the PYtest¹.

The cutoff point of 50 DPM was determined to be the mean +3SD of results obtained in patients who did not have *H. pylori*.

DPM = Disintegrations per minute

**Table 3: Factors which might cause sub-optimal breath test results**

<table>
<thead>
<tr>
<th>Factor</th>
<th>Result</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Recent antibiotic or bismuth (Pepto-Bismol, etc.)</td>
<td>false neg.</td>
<td>Relapse of partially treated <em>Hp</em> may take 1–4 weeks.</td>
</tr>
<tr>
<td>Omeprazole (or other proton pump inhibitors)</td>
<td>false neg.</td>
<td>These agents suppress <em>Hp</em> in 40% of patients. Discontinue for at least 2 weeks before</td>
</tr>
</tbody>
</table>
performing the PYtest. 

<table>
<thead>
<tr>
<th>Resective gastric surgery</th>
<th>false neg.</th>
<th>Isotope may empty rapidly from the stomach.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Resective gastric surgery</td>
<td>false pos.</td>
<td>Patient may be achlorhydric and have bacterial overgrowth (non-Hp urease).</td>
</tr>
<tr>
<td>Food in stomach (also bezoar, gastroparesis)</td>
<td>unknown</td>
<td>Isotope may not come into contact with gastric mucosa. Patient may be achlorhydric and/or have bacterial overgrowth (non-Hp urease).</td>
</tr>
</tbody>
</table>

**Expected Values**

As shown in Figure 4 approximately 30% of patients tested will be positive for *H. pylori*.

**Figure 4: Histogram showing DPM distribution for the PYtest*.**

<table>
<thead>
<tr>
<th>DPM Group</th>
<th>Frequency</th>
</tr>
</thead>
<tbody>
<tr>
<td>1-3</td>
<td>40</td>
</tr>
<tr>
<td>4-7</td>
<td>35</td>
</tr>
<tr>
<td>8-12</td>
<td>30</td>
</tr>
<tr>
<td>13-16</td>
<td>25</td>
</tr>
<tr>
<td>17-20</td>
<td>20</td>
</tr>
<tr>
<td>21-24</td>
<td>15</td>
</tr>
<tr>
<td>25-28</td>
<td>10</td>
</tr>
<tr>
<td>29-32</td>
<td>5</td>
</tr>
<tr>
<td>33-36</td>
<td>2</td>
</tr>
<tr>
<td>37-40</td>
<td>1</td>
</tr>
</tbody>
</table>

*Note: DPM groupings were calculated on a logarithmic scale. Empty DPM groupings were not included. Chart includes all patients from Studies 1 and 2. Frequency of DPM group includes samples with DPM < Group Name.

\[
DPM = \text{Disintegrations per minute}
\]

**Gold Standard** = Agreement between histology and CLOtest

If the capsule is damaged or appears abnormal in any way, it may give inaccurate results.

**HOW SUPPLIED**

PYtest Capsules, clear gelatin capsules each containing 1 μCi of 14C-urea in unit dose packages of 1,
PYtest Kit (14C-urea breath test) is also supplied as a kit containing a PYtest Capsule and breath collection equipment.

The PYtest Capsule has a shelf life of two years. The expiration date is printed on the capsule label. PYtest Capsules and Kit should be stored at 15–30 °C (59–86 °F) in an area designated by each individual institution's regulations.

Rx Only (USA)
U.S. Patent Nos. 4,748,113; 4,830,010
PYtest*

14C-UREA BREATH TEST CAPSULES

FOR THE DETECTION OF HELICOBACTER PYLORI

Capsules pour test d’haleine d’uree 14C

pour la détection de l’Helicobacter pylori • Contenu – 10 capsules PYtest* contenant chacune 1 μCi d’uree 14C

Pour des informations sur le dosage, se reporter à la notice d’emballage

Urée 14C (1/2 vie 5730 ans, émissions β 156keV [max.])

Pour diagnostic in vitro • Sur prescription médicale uniquement • Conserver à une température de 15 °C à 30 °C

Cápsulas de test de aliento de la urea 14C

para la detección de la Helicobacter pylori • Contenido – 10 cápsulas PYtest* con 1 μCi de urea 14C cada una

Para información sobre la dosificación, vea el prospecto incluido en el envase

Uréa 14C (5730yr 1/2, 156keV [max.] emisión β)

Para uso diagnóstico in vitro • Venta sólo bajo receta • Conservar a 15 °C – 30 °C

Cápsulas de teste do hálito de ureia-14C

para deteção da bactéria Helicobacter pylori • Conteúdo – 10 cápsulas PYtest* contendo, cada uma, 1 μCi de ureia-14C

Para obter informações sobre a dosagem, consulte o folheto da embalagem

Ureia-14C (5730 yr 1/2, 156 keV [max.] emissão β)

Para utilização em diagnóstico in vitro • Venda apenas mediante receita médica • Armazenar a 15 °C – 30 °C

For In Vitro Diagnostic Use

Rx Only

Store at 15°C–30°C (59ºF–86ºF)

10 (10 x 1) REF 60442

Distributed in the USA by Avanos Medical Sales, LLC, 5405 Windward Parkway, Alpharetta, GA 30004 USA.

In USA, 1-844-428-2667. www.avanos.com Avanos Medical, Inc., 5405 Windward Parkway, Alpharetta, GA 30004 USA. Avanos Medical Belgium BVBA, Leonardo Da Vinci laan 1, 1930 Zaventem, Belgium. Sponsored in Australia by Avanos Medical Australia Pty Ltd, 475 Victoria Avenue, Chatswood, NSW 2067, Australia.

* Registered Trademark or Trademark of Avanos Medical, Inc., or its affiliates. © 2018 AVNS. All rights reserved.

20-M1-022-01 / 7021175

---

PYtest*

14C-UREA BREATH TEST CAPSULES

FOR THE DETECTION OF HELICOBACTER PYLORI

Contents – 10 PYtest* Capsules each containing 1 μCi 14C-Urea

For dosage information, please see package insert.
Product Information

**Product Type**
HUMAN PRESCRIPTION DRUG

**Route of Administration**
ORAL

**Active Ingredient/Active Moiety**

<table>
<thead>
<tr>
<th>Ingredient Name</th>
<th>Basis of Strength</th>
<th>Strength</th>
</tr>
</thead>
<tbody>
<tr>
<td>Urea C-14 (UNII: WBZ6M63TEE) (Urea C-14 - UNII:WBZ6M63TEE)</td>
<td>Urea C-14</td>
<td>1 uCi</td>
</tr>
</tbody>
</table>

**Product Characteristics**

<table>
<thead>
<tr>
<th>Color</th>
<th>YELLOW (Light Lemon Yellow)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Shape</td>
<td>CAPSULE (Oval)</td>
</tr>
<tr>
<td>Flavor</td>
<td></td>
</tr>
</tbody>
</table>

**Contains**

**Packaging**

<table>
<thead>
<tr>
<th>#</th>
<th>Item Code</th>
<th>Package Description</th>
<th>Marketing Start Date</th>
<th>Marketing End Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>NDC:42536-6044-1</td>
<td>1 in 1 PACKAGE</td>
<td>05/09/1997</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>NDC:42536-6044-2</td>
<td>10 in 1 PACKAGE; Type 0: Not a Combination Product</td>
<td>05/09/1997</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>NDC:42536-6044-3</td>
<td>100 in 1 PACKAGE; Type 0: Not a Combination Product</td>
<td>05/09/1997</td>
<td></td>
</tr>
</tbody>
</table>

**Marketing Information**

<table>
<thead>
<tr>
<th>Marketing Category</th>
<th>Application Number or Monograph Citation</th>
<th>Marketing Start Date</th>
<th>Marketing End Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>NDA</td>
<td>NDA020617</td>
<td>05/09/1997</td>
<td></td>
</tr>
</tbody>
</table>

**Labeler** - Avent, Inc. (049316284)